Related Experiment Videos
[Safety, antigenic activity, and epidemiologic effectiveness of live mumps vaccine from strain L-3. II. Antigenic
Abstract:
The results obtained in the study of the antigenic activity and epidemiological effectiveness of live parotitis vaccine prepared from strain L-3 are presented. Children aged 3-7 years were shown to react to the injection of this preparation by the moderate production of virus-neutralizing antibodies (the percentage of persons with antibody titers of 1:8 and higher increased from 26.5 to 64.4). The most intensive antibody production was stimulated by the vaccines containing 40,000 and 20,000 viral particles in 1 vaccination dose. In seropositive children no significant shift in the antibody content was observed irrespective of the batch of the vaccine used. During 1 1/2 years of observation the morbidity rate of epidemic parotitis among children immunized with live parotitis vaccine was 6.9 times lower than among the unvaccinated children in the same groups and 8.8 times lower than among the children used as external control. The effectiveness rate of the vaccine was on the average 85.4% and 88.6%. The vaccines containing 40,000 and 20,000 HADU50 were found to have greater epidemiological effectiveness, while the epidemiological effectiveness of the vaccine containing 5,000 HADU50 was somewhat less. The effect of vaccination depended not only on the dose of the antigen and the initial state of the vaccines, but also on the extent of the coverage of children with vaccination in organized groups.
Insights
Live parotitis vaccine effectively protects children against mumps. Immunization significantly reduced illness rates, demonstrating high vaccine effectiveness and robust antibody production in young children.
Area of Science:
- Immunology
- Vaccinology
- Epidemiology
Context:
- Live parotitis vaccine (strain L-3) was evaluated for its antigenic activity and epidemiological effectiveness.
- Children aged 3-7 years were the study population.
Purpose:
- To assess the immune response (antibody production) to the live parotitis vaccine.
- To determine the epidemiological effectiveness and morbidity reduction in immunized versus unvaccinated children.
Summary:
- The vaccine induced moderate virus-neutralizing antibody production in children, with higher antibody levels observed with vaccine doses of 40,000 and 20,000 viral particles.
- Over 1.5 years, immunized children experienced significantly lower mumps morbidity (6.9 times lower than unvaccinated, 8.8 times lower than external control).
- Vaccine effectiveness averaged 85.4% and 88.6%, with higher doses (40,000 and 20,000 HADU50) showing greater effectiveness.
Impact:
- The study confirms the significant protective effect of live parotitis vaccine against mumps in children.
- Vaccine effectiveness is influenced by antigen dose, vaccine batch, and vaccination coverage rates within groups.
- Findings support the use of live parotitis vaccine for public health interventions to control mumps outbreaks.